Edge Therapeutics Inc.

(EDGE) Trade

Symbol has changed to a new ticker symbol

(PDSB)

By |

Profile

Edge Therapeutics Inc operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. Its core objective lies in the development and commercialization of therapies for serious unmet medical conditions, especially neurological disorders in the hospital setting. The company is currently evaluating EG-1962, its lead product candidate, in the Phase 3 NEWTON 2 study in adult patients with aneurysmal subarachnoid hemorrhage (aSAH). Edge uses its trademark platform known as Precisa, which enables the creation of polymer-based therapeutics capable of delivering directly to the site of injury, without affecting other areas of the body resulting in side-effects.

Contact Information

Website: www.edgetherapeutics.com
Email: ir@edgetherapeutics.com
Main Phone: +1 800 208-3343
Address: 300 Connell Drive
Address 2: Suite 4000
State: NJ
City / Town: Berkeley Heights
Country: USA
Postal Code: 07922

Issuer Information

Exchange: NSC
CEO: Brian A. Leuthner
Employees: 10
NAICS: Pharmaceutical Preparation Manufacturing(325412)


Gathering Data... Please wait

Profile

Edge Therapeutics Inc operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. Its core objective lies in the development and commercialization of therapies for serious unmet medical conditions, especially neurological disorders in the hospital setting. The company is currently evaluating EG-1962, its lead product candidate, in the Phase 3 NEWTON 2 study in adult patients with aneurysmal subarachnoid hemorrhage (aSAH). Edge uses its trademark platform known as Precisa, which enables the creation of polymer-based therapeutics capable of delivering directly to the site of injury, without affecting other areas of the body resulting in side-effects.

Contact Information

Website: www.edgetherapeutics.com
Email: ir@edgetherapeutics.com
Main Phone: +1 800 208-3343
Address: 300 Connell Drive
Address 2: Suite 4000
State: NJ
City / Town: Berkeley Heights
Country: USA
Postal Code: 07922

Issuer Information

Exchange: NSC
CEO: Brian A. Leuthner
Employees: 10
NAICS: Pharmaceutical Preparation Manufacturing(325412)
(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A
  Last 3 Mo Last 12 Mo
Number of Insider Trades 4 37
Number of Buys 0 1
Number of Sells 4 36
Net Activity -12500 -84331
Last 10 Buys Shares
James J. Loughlin 1,000
James J. Loughlin 1,000
James J. Loughlin 1,000
James J. Loughlin 1,000
James J. Loughlin 1,000
James J. Loughlin 1,000
James J. Loughlin 1,000
James J. Loughlin 1,000
James I. Healy 1,000
James I. Healy 1,000
Last 10 Sell Shares
R. Loch Macdonald 1,000
R. Loch Macdonald 1,000
R. Loch Macdonald 1,000
R. Loch Macdonald 1,000
Brian A. Leuthner 1,000
Brian A. Leuthner 1,000
Brian A. Leuthner 1,000
R. Loch Macdonald 1,000
Brian A. Leuthner 1,000
R. Loch Macdonald 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 21 21 21 21
Low Target Price Estimate 21 21 21 21
Mean Target Price Estimate 21 21 21 21
Standard Deviation 0 0 0 0
Date of Most Recent Estimate 03/01/18 03/01/18 03/01/18 03/01/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 0 0 0 1
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 0 0 0 1